Acne
31654121
Practical management of acne for clinicians: An international consensus from the Global Alliance to Improve Outcomes in Acne
&NA; Scientific advances are continually improving the knowledge of acne and contributing to the refinement of treatment options; it is important for clinicians to regularly update their practice patterns to reflect current standards. The Global Alliance to Improve Outcomes in Acne is an international group of dermatologists with an interest in acne research and education that has been meeting regularly since 2001. As a group, we have continuously evaluated the literature on acne. This supplement focuses on providing relevant clinical guidance to health care practitioners managing patients with acne, with an emphasis on areas where the evidence base may be sparse or need interpretation for daily practice.
Journal of the American Academy of Dermatology
Diane M Thiboutot Brigitte Dreno Abdullah Abanmi Andrew F Alexis Elena Araviiskaia Maria Isabel Barona Cabal Vincenzo Bettoli Flordeliz Abad Casintahan Steve Chow Adilson da Costa T el Ouazzani Chee Leok Goh Harald p M Gollnick Minerva Gomez Nobukazu Hayashi Maria Isabel Herane Herane Juan Honeyman Sewon Kang Lajos V Kemeny Raj Kubba Julien Lambert Alison M Layton James J Leyden Jose Luis Lopez-Estebaranz Nopadon Noppakun Falk Rudiger Ochsendorf Cristina Oprica Beatriz Orozco Montserrat Perez Jaime Piquero-Martin JoAnn See Dae Hun Suh Jerry Tan Vicente Torres Lozada Patricia Troielli Leihong Xiang
73728348
From pathogenesis of acne vulgaris to anti acne agents
Acne vulgaris is a cutaneous chronic inflammatory disorder with complex pathogenesis. Four factors play vital roles in acne pathophysiology: hyperseborrhea and dysseborrhea, altered keratinization of the pilosebaceous duct, Cutibacterium acnes (C. acnes) and inflammation. The main hormones responsible for the development of acne vulgaris include androgens, insulin and insulin like growth factor 1. Other factors involved in this process are corticotropin releasing hormone, a melanocyte stimulating hormone and substance P. Wnt/b catenin signaling pathway, phosphoinositide 3 kinase (PI3K)/Akt pathway, mitogen activated protein kinase pathway, adenosine 5' monophosphate activated protein kinase pathway and nuclear factor kappa B pathway participate in the modulation of sebocyte, keratinocyte and inflammatory cell (e.g. lymphocytes, monocytes, macrophages, neutrophils) activity. Among all the triggers and pathways mentioned above, IGF 1 induced PI3K/Akt/Forkhead box protein O1/mammalian target of rapamycin (mTOR) C1 pathway is the most important signaling responsible for acne pathogenesis. Commonly used anti acne agents include retinoids, benzoyl peroxide, antibiotics and hormonal agents (e.g. spironolactone, combination oral contraceptive and flutamide) New approaches including peroxisome proliferator activated receptor g modifier, melanocortin receptor antagonists, epigallocatechin 3 gallate, metformin, olumacostat glasaretil, stearoyl CoA desaturase inhibitor omiganan pentahydrochloride, KDPT, afamelanotide, apremilast and biologics have been developed as promising treatments for acne vulgaris. Although these anti acne agents have various pharmacological effects against the diverse pathogenesis of acne, all of them have a synergistic mode of action, the attenuation of Akt/mTORC1 signaling and enhancement of p53 signal transduction. In addition to drug therapy, diet with no hyperglycemic carbohydrates, no milk and dairy products is also beneficial for treatment of acne.
Archives of Dermatological Research
Tianxin Cong Dan Hao Xiang Wen Xiao-hua Li Gu He Xian Jiang
205513065
Guidelines of care for the management of acne vulgaris.
Acne is one of the most common disorders treated by dermatologists and other health care providers. While it most often affects adolescents, it is not uncommon in adults and can also be seen in children. This evidence based guideline addresses important clinical questions that arise in its management. Issues from grading of acne to the topical and systemic management of the disease are reviewed. Suggestions on use are provided based on available evidence.
Journal of the American Academy of Dermatology
Andrea L Zaenglein Arun L Pathy Bethanee J Schlosser Ali Alikhan Hilary E Baldwin Diane S Berson Whitney P Bowe Emmy M Graber Julie C Harper Sewon Kang Jonette E Keri James J Leyden Rachel V Reynolds Nanette B Silverberg Linda Stein Gold Megha M Tollefson Jonathan S Weiss Nancy C Dolan Andrew A Sagan Mackenzie Stern Kevin M Boyer Reva Bhushan
3444092
Acne prevalence and associations with lifestyle: a cross sectional online survey of adolescents/young adults in 7 European countries
Although acne vulgaris is a common skin disorder, limited epidemiological data exist specifically for European populations.
Journal of the European Academy of Dermatology and Venereology JEADV
Pierre Wolkenstein Alena Machovcova J C Szepietowski Dominique Tennstedt S Veraldi Alain Delarue
1302872
Acne vulgaris: The metabolic syndrome of the pilosebaceous follicle.
Acne vulgaris is an epidemic inflammatory disease of the human sebaceous follicle and represents the most common skin disease affecting about 85% of adolescents in Westernized populations. Acne vulgaris is primarily a disease of wealthy countries and exhibits higher prevalence rates in developed compared with developing countries. No acne has been found in non Westernized populations still living under Paleolithic dietary conditions constraining hyperglycemic carbohydrates, milk, and dairy products. The high prevalence rates of adolescent acne cannot be explained by the predominance of genetic factors but by the influence of a Western diet that overstimulates the key conductor of metabolism, the nutrient and growth factor sensitive kinase mTORC1. Increased mTORC1 activity has been detected in lesional skin and sebaceous glands of acne patients compared with acne free controls. Increased mTORC1 signaling is a characteristic feature of insulin resistance, obesity, type 2 diabetes mellitus, cancer, and neurodegenerative diseases. Acne vulgaris is a family member of mTORC1 driven diseases of civilization and represents the MetS of the sebaceous follicle.
Clinics in dermatology
Bodo C Melnik
635373
Efficacy and adverse events of oral isotretinoin for acne: a systematic review
Despite many years of clinical use of isotretinoin, a comprehensive review of evidence for isotretinoin therapy in patients with acne is lacking. We searched MEDLINE, Embase, Cochrane Central, relevant web pages and bibliographies for randomized controlled trials in acne evaluating isotretinoin vs. control (placebo or other therapy) Data were extracted and summarized descriptively. Eleven trials were identified (total 760 patients randomized) containing mostly men. Mean treatment ages ranged from 18 to 47*9 years and participants generally had moderate to severe acne. Across all trials, isotretinoin therapy reduced acne lesion counts by a clinically relevant amount, and always by a greater amount than control, which was either placebo (two studies) oral antibiotics (seven studies) or other control (two studies) Across trials with an overall low risk of bias, two of three demonstrated statistically significant differences between isotretinoin and control. The frequency of adverse events was twice as high with isotretinoin (751 events) than with control (388 events) More than half of all adverse events were dermatological and related to dryness. Adverse events from isotretinoin causing participant withdrawal from trials (12 patients) included Stevens Johnson syndrome, cheilitis, xerosis, acne flare, photophobia, elevated liver enzymes, decreased appetite, headaches and depressed mood. This review suggests that isotretinoin is effective in reducing acne lesion counts, but adverse events are common. This study was registered with PROSPERO number CRD42015025080.
The British journal of dermatology
I A Vallerand Ryan T Lewinson Megan S Farris Christopher D Sibley Michele L Ramien Andrew G M Bulloch Scott B Patten
42897425
Isotretinoin and lymecycline treatments modify the skin microbiota in acne
Oral retinoids and tetracyclines have a major role in acne treatment. Here, we report for the first time the effect of isotretinoin and lymecycline therapy on the skin microbiota in cheek, back and armpit swab samples of acne vulgaris patients using 16S ribosomal RNA (16S rRNA) gene amplicon sequencing. Propionibacterium acnes was the most common in sebaceous areas of healthy and untreated acne skin and more abundant in back than cheek samples. Five taxa, including a Streptococcus taxon, differed significantly between the cheek samples of healthy controls and acne patients, and acne severity was positively correlated with the abundance of Propionibacterium. Both treatments reduced clinical acne grades and the abundance of Propionibacterium, while the abundance of several other taxa was significantly higher in treated cheek samples compared with untreated ones. Less variation was observed in back samples and none in armpit samples. There were no differences in alpha diversity between control and acne patients in any of the sampled skin areas, but the diversity of the microbiota on the cheek and the back was significantly increased after acne treatments. This study provides insight into the skin microbiota in acne and how it is modulated by systemic acne treatment.
Experimental dermatology
Hanna-Leena Kelhala Velma T E Aho Nanna Fyhrquist Pedro Pereira Minna E Kubin Lars Paulin Riitta Palatsi Petri Auvinen Kaisa Tasanen Antti Lauerma
42042680
Can We Define Acne as a Chronic Disease?
There is widespread misunderstanding of acne amongst both the medical and lay community, who often perceive the condition to be a simple, self limited affliction of adolescents. Because many think that the disease "will go away on its own," they do not feel an urgency to aggressively treat acne. However, very often the reality is that acne treatment can be quite difficult. Furthermore, acne can be a devastating disease for the patient, since it manifests on visible body parts and in children near puberty, who are vulnerable both socially and psychologically. Most typically, acne is not an acute disease but rather a condition that continuously changes in its distribution and severity. Usually, acne treatment is necessary for many months and sometimes years. Despite treatment, acne may cause scarring and associated negative psychological effects. It is important for both patients and physicians to be aware that very effective treatments are available. It is also important to realize that new studies have proven the benefit of maintenance therapy with topical retinoids; these agents can minimize the potential for relapse, which is part of the natural history of acne. This article reviews the evidence suggesting that acne is a chronic disease in at least a subset of individuals. The members of the Global Alliance to Improve Outcomes in Acne believe that acne should be recognized and investigated as a chronic disease. This will change expectations of clinical trial design and treatment and will highlight gaps in the knowledge of acne epidemiology. The result should be an improvement in patient outcomes.
American journal of clinical dermatology
Harald p M Gollnick Andrew Y Finlay Neil H Shear on behalf of the Global Alliance to Improve Outcomes Acne
4534961
Autoinflammation in pyoderma gangrenosum and its syndromic form (pyoderma gangrenosum, acne and suppurative hidradenitis)
Pyoderma gangrenosum (PG) is a rare skin disease characterized clinically by ulcers with undermined borders, and histologically by neutrophil rich infiltrates. PG may occur alone, in syndromic forms or associated with systemic diseases, such as inflammatory bowel disease and haematological or rheumatological disorders.
The British journal of dermatology
Angelo Valerio Marzano Giovanni Damiani Isabella Ceccherini E Berti Marco Gattorno Massimo Cugno
19815486
European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa
Hidradenitis suppurativa/acne inversa (HS) is a chronic, inflammatory, recurrent, debilitating skin disease of the hair follicle that usually presents after puberty with painful, deep seated, inflamed lesions in the apocrine gland bearing areas of the body, most commonly the axillae, inguinal and anogenital regions. A mean disease incidence of 6.0 per 100 000 person years and an average prevalence of 1% has been reported in Europe. HS has the highest impact on patients' quality of life among all assessed dermatological diseases. HS is associated with a variety of concomitant and secondary diseases, such as obesity, metabolic syndrome, inflammatory bowel disease, e.g. Crohn's disease, spondyloarthropathy, follicular occlusion syndrome and other hyperergic diseases. The central pathogenic event in HS is believed to be the occlusion of the upper part of the hair follicle leading to a perifollicular lympho histiocytic inflammation. A highly significant association between the prevalence of HS and current smoking (Odds ratio 12.55) and overweight (Odds ratio 1.1 for each body mass index unit) has been documented. The European S1 HS guideline suggests that the disease should be treated based on its individual subjective impact and objective severity. Locally recurring lesions can be treated by classical surgery or LASER techniques, whereas medical treatment either as monotherapy or in combination with radical surgery is more appropriate for widely spread lesions. Medical therapy may include antibiotics (clindamycin plus rifampicine, tetracyclines) acitretin and biologics (adalimumab, infliximab) A Hurley severity grade relevant treatment of HS is recommended by the expert group following a treatment algorithm. Adjuvant measurements, such as pain management, treatment of superinfections, weight loss and tobacco abstinence have to be considered.
Journal of the European Academy of Dermatology and Venereology JEADV
C C Zouboulis Nemesha Desai L Emtestam Robert Emil Hunger D Ioannides Istvan Juhasz Jan Lapins Lukasz Matusiak Errol P Prens Jean Revuz S Schneider-Burrus Jacek Cezary Szepietowski H H Zee Gregor B E Jemec